who's who

3 Houston innovators to know this week

This week's roundup of Houston innovators includes Barbar Burger of Chevron, David Aaronson of REVs, and Andrea Young of DonateStock. Courtesy photos

Editor's note: In this week's roundup of Houston innovators to know, I'm introducing you to three local innovators across industries — from energy to fintech — recently making headlines in Houston innovation.

Barbara Burger, vice president of innovation at Chevron and president of Chevron Technology Ventures

The InnovationMap Awards will celebrate Barbara Burger, vice president of innovation at Chevron and president of Chevron Technology Ventures, as this year's Trailblazer Award honoree. Photo courtesy of CTV

The inaugural Trailblazer Award at the 2021 InnovationMap Awards event was established to honor a Houston innovation leader and advocate who's making a lasting impact on the Houston innovation community. Barbara Burger, vice president of innovation at Chevron and president of Chevron Technology Ventures, was selected to receive award.

"I am deeply honored to be recognized for my contributions to the Houston Innovation Ecosystem. I moved to Houston in 2013 and in short order was included and saw ways I could contribute. That is a great welcome! While I am proud of my contributions and our progress, we are just getting started," Burger says.

Burger leads Chevron's corporate venture arm, Chevron Technology Ventures, which has invested millions in the future of energy technology. This type of corporate venture activity — especially in a city with so many Fortune 500 companies — plays a key role in an innovation community. Click here to read more.

David Aaronson, founder of REVS

David Aaronson of REVS shares his EV entrepreneurial journey on the Houston Innovators Podcast. Photo courtesy of REVS

It might not be today, and it might not be tomorrow, but electric vehicles are coming into Texas at an increasing rate. EVolve Houston, founded in part by the city, predicts that EV sales locally will make up 30 percent of annual new car sales by 2030. Aaronson says they reported that Houston has around 15,000 EVs on the road today, but by 2030, that's going to be 600,000.

"If it's not 2030 it's going to be 2032, because it's all the manufacturers are making," David Aaronson, founder of REVS, says on this week's episode of the Houston Innovators Podcast. "It's just a matter of time."

Aaronson, a Houston real estate veteran, founded Refuel Electric Vehicle Solutions, or REVS, last year to become the go-between for multifamily property owners and managers and the charging technology providers. Click here to read more and stream the episode.

Andrea Young, co-founder and CEO of DonateStock

DonateStock, a Houston fintech company that simplifies the stock donation process, has officially launched. Image courtesy of DonateStock

A few years back, Andrea Young donated some of her stock, and the process, while having its perks, wasn't worth the trouble.

"I valued the immense benefits stock donations provided me as an investor while simultaneously helping a nonprofit," Young says of her early experience with donating stock. "I enjoyed the significant tax advantages that allowed me to avoid capital gains taxes while deducting the full market value of my gifted stock. However, I found the entire process time consuming and cumbersome, which led to the end of my stock donation journey."

When the pandemic hit and nonprofits were greatly impacted, Young and her co-founder saw an opportunity to found DonateStock to help drive donations and guide nonprofits and donors alike through the process. During its beta testing phase, the company partnered with almost 100 nonprofits. Click here to read more.

Trending News

 
 

Promoted

A research team housed out of the newly launched Rice Biotech Launch Pad received funding to scale tech that could slash cancer deaths in half. Photo via Rice University

A research funding agency has deployed capital into a team at Rice University that's working to develop a technology that could cut cancer-related deaths in half.

Rice researchers received $45 million from the National Institutes of Health's Advanced Research Projects Agency for Health, or ARPA-H, to scale up development of a sense-and-respond implant technology. Rice bioengineer Omid Veiseh leads the team developing the technology as principal investigator.

“Instead of tethering patients to hospital beds, IV bags and external monitors, we’ll use a minimally invasive procedure to implant a small device that continuously monitors their cancer and adjusts their immunotherapy dose in real time,” he says in a news release. “This kind of ‘closed-loop therapy’ has been used for managing diabetes, where you have a glucose monitor that continuously talks to an insulin pump. But for cancer immunotherapy, it’s revolutionary.”

Joining Veiseh on the 19-person research project named THOR, which stands for “targeted hybrid oncotherapeutic regulation,” is Amir Jazaeri, co-PI and professor of gynecologic oncology at the University of Texas MD Anderson Cancer Center. The device they are developing is called HAMMR, or hybrid advanced molecular manufacturing regulator.

“Cancer cells are continually evolving and adapting to therapy. However, currently available diagnostic tools, including radiologic tests, blood assays and biopsies, provide very infrequent and limited snapshots of this dynamic process," Jazaeri adds. "As a result, today’s therapies treat cancer as if it were a static disease. We believe THOR could transform the status quo by providing real-time data from the tumor environment that can in turn guide more effective and tumor-informed novel therapies.”

With a national team of engineers, physicians, and experts across synthetic biology, materials science, immunology, oncology, and more, the team will receive its funding through the Rice Biotech Launch Pad, a newly launched initiative led by Veiseh that exists to help life-saving medical innovation scale quickly.

"Rice is proud to be the recipient of the second major funding award from the ARPA-H, a new funding agency established last year to support research that catalyzes health breakthroughs," Rice President Reginald DesRoches says. "The research Rice bioengineer Omid Veiseh is doing in leading this team is truly groundbreaking and could potentially save hundreds of thousands of lives each year. This is the type of research that makes a significant impact on the world.”

The initial focus of the technology will be on ovarian cancer, and this funding agreement includes a first-phase clinical trial of HAMMR for the treatment of recurrent ovarian cancer that's expected to take place in the fourth year of THOR’s multi-year project.

“The technology is broadly applicable for peritoneal cancers that affect the pancreas, liver, lungs and other organs,” Veiseh says. “The first clinical trial will focus on refractory recurrent ovarian cancer, and the benefit of that is that we have an ongoing trial for ovarian cancer with our encapsulated cytokine ‘drug factory’ technology. We'll be able to build on that experience. We have already demonstrated a unique model to go from concept to clinical trial within five years, and HAMMR is the next iteration of that approach.”

Trending News

 
 

Promoted